Evolent Health, Inc. (NYSE:EVH) Receives Consensus Recommendation of “Buy” from Analysts

Evolent Health, Inc. (NYSE:EVH) has earned an average rating of “Buy” from the thirteen research firms that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation, eleven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among analysts that have covered the stock in the last year is $21.92.

Several research analysts have recently issued reports on the company. Truist Financial cut their price target on Evolent Health from $24.00 to $20.00 and set a “buy” rating for the company in a research note on Monday, January 13th. JMP Securities lowered their price target on shares of Evolent Health from $27.00 to $18.00 and set a “market outperform” rating on the stock in a research report on Friday, January 10th. Barclays cut their price objective on Evolent Health from $39.00 to $19.00 and set an “overweight” rating for the company in a research report on Monday, November 11th. Royal Bank of Canada dropped their price target on Evolent Health from $20.00 to $17.00 and set an “outperform” rating for the company in a research report on Tuesday, January 14th. Finally, Stephens downgraded Evolent Health from an “overweight” rating to an “equal weight” rating and reduced their price objective for the company from $38.00 to $16.00 in a research report on Friday, November 8th.

Institutional Trading of Evolent Health

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Quarry LP purchased a new position in shares of Evolent Health in the 2nd quarter worth about $32,000. Covestor Ltd grew its stake in Evolent Health by 138.1% during the third quarter. Covestor Ltd now owns 1,424 shares of the technology company’s stock worth $40,000 after buying an additional 826 shares during the period. GAMMA Investing LLC increased its position in shares of Evolent Health by 5,365.5% in the third quarter. GAMMA Investing LLC now owns 1,585 shares of the technology company’s stock worth $45,000 after acquiring an additional 1,556 shares in the last quarter. Canada Pension Plan Investment Board purchased a new position in shares of Evolent Health in the 2nd quarter valued at $61,000. Finally, Point72 DIFC Ltd acquired a new position in shares of Evolent Health during the 2nd quarter valued at $148,000.

Evolent Health Stock Performance

Shares of EVH opened at $10.02 on Monday. The company has a market capitalization of $1.17 billion, a PE ratio of -11.01 and a beta of 1.45. Evolent Health has a 52-week low of $9.88 and a 52-week high of $35.00. The company has a 50-day simple moving average of $11.79 and a 200-day simple moving average of $20.73. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 0.58.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.